BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21555306)

  • 1. Soluble Fas and Fas ligand in pregnancy: influence of hypertension.
    Karthikeyan VJ; Lip GY; Baghdadi S; Lane DA; Beevers DG; Blann AD
    Angiology; 2012 Jan; 63(1):35-8. PubMed ID: 21555306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of soluble fas and soluble fas ligand in serum of patients with complete hydatidiform moles.
    Soni S; Rath G; Deval R; Salhan S; Mishra AK; Saxena S
    Am J Reprod Immunol; 2011 Sep; 66(3):230-6. PubMed ID: 21385271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
    Naumnik W; Izycki T; Ossolinska M; Chyczewska E
    Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors.
    Kondera-Anasz Z; Mielczarek-Palacz A; Sikora J
    Apoptosis; 2005 Oct; 10(5):1143-9. PubMed ID: 16151647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble fas antigen and soluble fas ligand in intrauterine growth restriction.
    Briana DD; Baka S; Boutsikou M; Liosi S; Vraila VM; Gourgiotis D; Hassiakos D; Malamitsi-Puchner A
    Neonatology; 2010; 97(1):31-5. PubMed ID: 19590243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
    Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
    Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum soluble Fas ligand is a promising marker of testicular toxicity induced by epirubicin in rats.
    Geng J; Fan J; Jiang HW; Fang ZJ; Wang X; Sun JL; Ding Q; Chen G
    Toxicol Lett; 2009 Apr; 186(2):96-103. PubMed ID: 19429229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome].
    Fu Y; Xiao QM; Wang T; Chen XH; Ai YH
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov; 18(11):691-4. PubMed ID: 17092425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the maternal and umbilical vein serum sFas/sFasL system in pregnancies complicated by preeclampsia with intrauterine growth retardation.
    Laskowska M; Laskowska K; Leszczyńska-Gorzelak B; Oleszczuk J
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):155-9. PubMed ID: 16169656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum and follicular fluid levels of soluble Fas and soluble Fas ligand in IVF cycles.
    Onalan G; Selam B; Onalan R; Ceyhan T; Cincik M; Pabuccu R
    Eur J Obstet Gynecol Reprod Biol; 2006 Mar; 125(1):85-91. PubMed ID: 16140454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Levels and clinic significance of serum soluble Fas and soluble Fas ligand in coal workers' pneumoconiosis].
    Yuan BJ; Liu ZZ; Ding XR; Zou JM
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 Feb; 24(2):96-8. PubMed ID: 16600114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of the sFas/sFasL system in psoriatic patients.
    Myśliwiec H; Baran A; Myśliwiec P; Górska M; Flisiak I
    Adv Med Sci; 2015 Mar; 60(1):64-8. PubMed ID: 25437350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum sFas/sFasL ratio in systemic lupus erythematosus (SLE) is a function of age.
    Turi MC; D'Urbano M; Celletti E; Alessandri C; Valesini G; Paganelli R
    Arch Gerontol Geriatr; 2009; 49 Suppl 1():221-6. PubMed ID: 19836636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST.
    Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Hérnandez G; Egido J;
    Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):168-74. PubMed ID: 17053166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sFas/sFasL ratio as a novel marker of inflammation in children with chronic kidney disease.
    Musiał K; Zwolińska D
    Clin Chim Acta; 2012 Dec; 414():7-11. PubMed ID: 22898262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B].
    Jun EJ; Han JY; Sun HS
    Korean J Hepatol; 2006 Dec; 12(4):507-14. PubMed ID: 17237628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF.
    Onalan G; Selam B; Baran Y; Cincik M; Onalan R; Gündüz U; Ural AU; Pabuccu R
    Hum Reprod; 2005 Sep; 20(9):2391-5. PubMed ID: 15932917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. sFas and sFas ligand and pediatric sepsis-induced multiple organ failure syndrome.
    Doughty L; Clark RS; Kaplan SS; Sasser H; Carcillo J
    Pediatr Res; 2002 Dec; 52(6):922-7. PubMed ID: 12438671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
    Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
    Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.